Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

July 7, 2021, 8:45 a.m. EDT

Biohaven's stock jumps 12% after saying its migraine drug had $93 million in sales in Q2

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Biohaven Pharmaceutical Holding Co. Ltd. /zigman2/quotes/204337507/composite BHVN -1.88% were up 12.1% in premarket trading on Wednesday after the company said its new migraine treatment brought in $93 million in sales in the second quarter of 2021. The drug, Nurtec Odt, can be used to treat and prevent migraines. It has generated a total of $200 million in net revenue since launching in the U.S. in March 2020. Biohaven's stock is up 15.3% for the year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -1.18% has gained 15.6%.

/zigman2/quotes/204337507/composite
US : U.S.: NYSE
$ 110.13
-2.11 -1.88%
Volume: 656,526
Dec. 1, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$7.35 billion
Rev. per Employee
$77,124
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,513.04
-53.96 -1.18%
Volume: 3.04B
Dec. 1, 2021 5:04p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.